[The clinico-hemodynamic effects of losartan in treating patients with chronic heart failure].
Clinical and hemodynamic effects were studied of the blockader of AII receptors lozartan in patients with chronic cardiac insufficiency (ChCI). Inclusion of losartan into the conventional therapy of ChCI is accompanied by a lowering of the functional class in patients and improvement of haemodynamic maintenance of the physical exercise performance as evidenced by veloergometry. An 8-week's course of lozartan therapy leads also to a decrease in the anterior-posterior dimensions of the left auricle and an increase in the left ventricular ejection fraction in ChCI patients.